Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse
Wrana, J. L.
He, H. H.
van der Kwast, T.
Zlotta, A. R.
Bristow, Robert G
Boutros, P. C.
AffiliationDepartment of Surgery, Division of Urology, University of Toronto, Toronto, ON, Canada.
MetadataShow full item record
AbstractDriver gene mutations that are more prevalent in metastatic, castration-resistant prostate cancer (mCRPC) than localized disease represent candidate prognostic biomarkers. We analyze 1,844 localized (1,289) or mCRPC (555) tumors and quantify the prevalence of 113 somatic driver single nucleotide variants (SNVs), copy number aberrations (CNAs), and structural variants (SVs) in each state. One-third are significantly more prevalent in mCRPC than expected while a quarter are less prevalent. Mutations in AR and its enhancer are more prevalent in mCRPC, as are those in TP53, MYC, ZNRF3 and PRKDC. ZNRF3 loss is associated with decreased ZNRF3 mRNA abundance, WNT, cell cycle & PRC1/2 activity, and genomic instability. ZNRF3 loss, RNA downregulation and hypermethylation are prognostic of metastasis and overall survival, independent of clinical and pathologic indices. These data demonstrate a strategy for identifying biomarkers of localized cancer aggression, with ZNRF3 loss as a predictor of metastasis in prostate cancer.
CitationFraser M, Livingstone J, Wrana JL, Finelli A, He HH, van der Kwast T, et al. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse [Internet]. Vol. 12, Nature Communications. Springer Science and Business Media LLC; 2021.
- Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
- Authors: Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ
- Issue date: 2019 Jul
- Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
- Authors: Kohli M, Tan W, Zheng T, Wang A, Montesinos C, Wong C, Du P, Jia S, Yadav S, Horvath LG, Mahon KL, Kwan EM, Fettke H, Yu J, Azad AA
- Issue date: 2020 Apr
- BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
- Authors: Shafran JS, Andrieu GP, Györffy B, Denis GV
- Issue date: 2019 Aug
- Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
- Authors: Liu W, Zheng SL, Na R, Wei L, Sun J, Gallagher J, Wei J, Resurreccion WK, Ernst S, Sfanos KS, Isaacs WB, Xu J
- Issue date: 2020 Dec
- CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer.
- Authors: Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS
- Issue date: 2006 Jan